These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 18781824)

  • 21. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator.
    Kurtz TW
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S9-16. PubMed ID: 15868121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beyond the classic angiotensin-receptor-blocker profile.
    Kurtz TW
    Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S19-26. PubMed ID: 18580862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rationale for double renin-angiotensin-aldosterone system blockade.
    Unger T; Stoppelhaar M
    Am J Cardiol; 2007 Aug; 100(3A):25J-31J. PubMed ID: 17666194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the treatment of hypertension: should they be used together?
    Verdecchia P; Angeli F; Mazzotta G; Ambrosio G; Reboldi G
    Curr Vasc Pharmacol; 2010 Nov; 8(6):742-6. PubMed ID: 20626343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of renal glomerular angiotensin II receptors by ace inhibition and AT1 receptor antagonism.
    Haddad G; Amiri F; Garcia R
    Regul Pept; 1997 Jan; 68(2):111-7. PubMed ID: 9110382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.
    Yusuf S
    Am J Cardiol; 2002 Jan; 89(2A):18A-25A; discussion 25A-26A. PubMed ID: 11835907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A meta-analysis of the effect of angiotensin receptor blockers and calcium channel blockers on blood pressure, glycemia and the HOMA-IR index in non-diabetic patients.
    Yang Y; Wei RB; Xing Y; Tang L; Zheng XY; Wang ZC; Gao YW; Li MX; Chen XM
    Metabolism; 2013 Dec; 62(12):1858-66. PubMed ID: 24050270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pathophysiological mechanisms of the renin-angiotensin system and its pharmacologic modification by ACE inhibitors or angiotensin II (type 1) receptor blockers in cardiovascular diseases].
    Huber K; Pachinger O; Pichler M; Klein W
    Z Kardiol; 1997 Apr; 86(4):239-50. PubMed ID: 9235795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New treatment strategies for patients with hypertension and insulin resistance.
    Kurtz TW
    Am J Med; 2006 May; 119(5 Suppl 1):S24-30. PubMed ID: 16563944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Telmisartan in high-risk cardiovascular patients.
    Weber MA
    Am J Cardiol; 2010 Jan; 105(1 Suppl):36A-43A. PubMed ID: 20102972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients.
    Watanabe M; Inukai K; Sumita T; Ikebukuro K; Ito D; Kurihara S; Ono H; Awata T; Katayama S
    Intern Med; 2010; 49(17):1843-7. PubMed ID: 20823643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pleiotropic effects of ARB in metabolic syndrome.
    Yamada S
    Curr Vasc Pharmacol; 2011 Mar; 9(2):158-61. PubMed ID: 21143168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different?
    Unger T
    Am J Cardiol; 1999 Nov; 84(10A):9S-15S. PubMed ID: 10588089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Are the pleiotropic effects of telmisartan clinically relevant?
    Rizos CV; Elisaf MS; Liberopoulos EN
    Curr Pharm Des; 2009; 15(24):2815-32. PubMed ID: 19689352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes.
    Mizuno M; Sada T; Kato M; Koike H
    Hypertens Res; 2002 Mar; 25(2):271-8. PubMed ID: 12047043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin.
    Clasen R; Schupp M; Foryst-Ludwig A; Sprang C; Clemenz M; Krikov M; Thöne-Reineke C; Unger T; Kintscher U
    Hypertension; 2005 Jul; 46(1):137-43. PubMed ID: 15939809
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renal expression of angiotensin receptors in long-term diabetes and the effects of angiotensin type 1 receptor blockade.
    Bonnet F; Candido R; Carey RM; Casley D; Russo LM; Osicka TM; Cooper ME; Cao Z
    J Hypertens; 2002 Aug; 20(8):1615-24. PubMed ID: 12172324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular and renal protection in type 2 diabetes mellitus: the role of calcium channel blockers.
    Nosadini R; Tonolo G
    J Am Soc Nephrol; 2002 Nov; 13 Suppl 3():S216-23. PubMed ID: 12466317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.